Additional file 1 of Quantitative evaluation of ocular vascularity and correlation analysis in patients with diabetic retinopathy by SMI and OCTA

Additional file 1: Supplementary Table S1. Comparison of retinal blood flow parameters in UWF-OCTA in patients with different stages of DR. Supplementary Table S2. Choroidal blood flow parameters in UWF-OCTA in patients with different stages of DR. Supplementary Table S3. Correlation analysis of retrobulbar hemodynamics and IOP, MAP. Supplementary Fig. S1. Scatter plots between IOP and retrobulbar hemodynamics. Supplementary Fig. S2. Scatter plots between MAP and retrobulbar hemodynamics. Supplementary Table S4. Receiver curves of retrobulbar hemodynamic parameters between NDR and VTDR. Supplementary Fig. S3. ROC curves of ocular hemodynamics between NDR and VTDR

Multivariate logistic regression in CRC patients between gene mutations and clinicopathological characteristics.

<p>LRT: likelihood ratio test; 95% CI: 95% confidence interval.</p

Frequency of the various KRAS and BRAFmutations.

<p>Panel A: KRAS mutations (codons12 & 13: n = 674; codon61: n = 672). Panel B: BRAF mutations (exon11: n = 676; exon15: n = 675). The data are presented as percentages (number of total samples).</p

Frequency of the various PIK3CA and NRAS mutations.

<p>Panel A: PIK3CA mutations (exon9: n = 643; exon20: n = 636). Panel B: NRAS mutations (codons12 & 13: n = 630; codon61: n = 643). The data are presented as percentages (number of total samples).</p

Characteristics of 676 CRC patients and association of gene mutations with clinicopathological parameters.

<p>^†: Colon is defined as right colon, transverse colon, left colon, <i>sig</i>moid colon, rectosigmoid transition zone. Colon</p><p>*: Proximal tumor is defined as right colon and transverse colon; distal tumor is defined as left colon, <i>sig</i>moid colon, rectosigmoid transition zone and rectum. Tumor location</p><p>↑Seventh edition of the AJCC/UICC TNM staging systems.</p

DataSheet_1_Comparison of the efficacy and safety in the treatment strategies between chemotherapy combined with antiangiogenic and with immune checkpoint inhibitors in advanced non-small cell lung cancer patients with negative PD-L1 expression: A network meta-analysis.pdf

BackgroundIn the first-line treatment of advanced non-small cell lung cancer (NSCLC), for those patients with negative PD-L1 expression, which treatment strategy has the better efficacy and safety between chemotherapy combined with antiangiogenic and with immune checkpoint inhibitors (ICIs) is still unclear due to the absence of head-to-head clinical trials. This study aims to answer the question by performing a systematic review and network meta-analysis (NMA).MethodsElectronic databases (PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov) were systematically searched accordingly to extract eligible studies from inception to October 2022, as well as the abstracts from the most recent main oncology congresses (American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), World Conference on Lung Cancer (WCLC), and European Society for Medical Oncology (ESMO)). Overall survival (OS), progression-free survival (PFS), and adverse events (AEs) of grades 3 to 5 were independently extracted and collected by two reviewers based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. We used Cochrane’s risk of bias tool for randomized controlled trials through RevMan 5.3 to ascertain the quality of the included studies. NMA with a Bayesian random-effects model was performed by R (version 4.0.4).ResultsAccording to the ranking list from OS-NMA, pembrolizumab combined with chemotherapy has the most effective ranking first (surface under the cumulative ranking (SUCRA) = 0.809844) (pooled HR = 0.65 [0.51–0.83]). On PFS, the triple combination of nivolumab/bevacizumab/chemotherapy ranks first (NMA estimate: HR = 0.35 [0.28–0.43]). On safety, in combination with chemotherapy, sintilimab has minimal toxicity, followed by pembrolizumab+chemo.ConclusionsIn advanced NSCLC patients with negative PD-L1 expression, pembrolizumab+chemo ranks first in the efficacy of OS and does not apparently increase the incidence of any grade ≥ 3 AE as compared with chemo alone. On PFS, pembrolizumab also has advantages, but for patients with squamous cell carcinoma, camrelizumab+chemo seems to be a better choice.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42021231441.</p

Investigation of Variants in UCP2 in Chinese Type 2 Diabetes and Diabetic Retinopathy

<div><p>Purpose</p><p>The aim of this study was to investigate variants in <i>UCP2</i> genes in type 2 diabetes mellitus (DM) and diabetic retinopathy (DR) in Chinese population.</p><p>Materials and Methods</p><p>We conducted a single nucleotide polymorphism-based and haplotype-based case-control study between the variants of <i>UCP2</i> and DM and between the variants of <i>UCP2</i> and DR in 479 Chinese patients with type 2 DM and 479 control subjects without DM. Two SNPs (rs660339 and rs659366) were selected as genetic markers.</p><p>Results</p><p>The risk allele C at <i>UCP2</i> rs660339 was closely associated with DM in Chinese population. There was significant difference in rs660339 between DM and controls (P = 0.0016; OR [95%CI]  = 1.37 (1.14–1.65)). Subjects who were homozygous of the C allele were more likely to develop DM. The frequency of C allele was higher in DM (58%) than in control (51%). But this locus didn't have a definite effect on the onset of non-proliferative diabetic retinopathy (NPDR) (P = 0.44; OR [95%CI]  = 0.80 (0.56–1.14)) and proliferative diabetic retinopathy (PDR) (P = 1.00; OR [95%CI]  = 0.99 (0.74–1.34)) comparing to subjects with DM without retinopathy (DWR), respectively. Moreover, the <i>UCP2</i> rs659366 polymorphism showed no significant difference between DM and control (P = 0.66; OR [95%CI]  = 1.10 (0.91–1.32)). However, there was a significant difference between PDR and DWR (P = 0.016; OR [95%CI]  = 0.66 (0.49–0.90)), but there was no difference between NPDR and DWR (P = 1.00; OR [95%CI]  = 0.96 (0.67–1.37)). Participants who carried the G allele at rs659366 were more likely to develop PDR. For the haplotype, C-A was present more frequently in DM than in control (16% vs 7%), indicating that it was risky, and T-A was present less in DM than in control (29% vs 35%). Haplotype frequencies in DR and DWR showed no significant difference (P = 0.068).</p><p>Conclusion</p><p>It was indicated that <i>UCP2</i> may be implicated in the pathogenesis of type 2 DM and DR in Chinese population.</p></div

Distributions of genotypes and alleles for the two variants in the DR and DWR.

<p>P value were calculated between DR and DWR.</p><p>Distributions of genotypes and alleles for the two variants in the DR and DWR.</p

Demographic characteristics of the patients with DM and control subjects.

<p>The results are expressed as mean ± SD.</p><p>Demographic characteristics of the patients with DM and control subjects.</p

Distributions of genotypes and alleles for the two variants in the DM and controls.

<p>P value were calculated between DM and control.</p><p>Distributions of genotypes and alleles for the two variants in the DM and controls.</p